# Use of rFXIII in Treatment of Congenital FXIII Deficiency, a Prospective Multi-centre Observational Study

> **NCT01862367** · — · COMPLETED · sponsor: **Novo Nordisk A/S** · enrollment: 30 (actual)

## Conditions studied

- Congenital Bleeding Disorder
- Congenital FXIII Deficiency

## Interventions

- **DRUG:** catridecacog

## Key facts

- **NCT ID:** NCT01862367
- **Lead sponsor:** Novo Nordisk A/S
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2013-05-17
- **Primary completion:** 2019-06-26
- **Final completion:** 2019-06-26
- **Target enrollment:** 30 (ACTUAL)
- **Last updated:** 2019-07-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01862367

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01862367, "Use of rFXIII in Treatment of Congenital FXIII Deficiency, a Prospective Multi-centre Observational Study". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT01862367. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*